Paul Herendeen - Zoetis CFO and Executive VP

ZTS Stock  USD 169.21  0.70  0.42%   

CFO

Mr. Paul S. Herendeen is Chief Financial Officer Executive Vice President of the Company since September 2 2014. He served as Executive Vice President and Chief Financial Officer of Warner Chilcott PLC a specialty pharmaceutical company from 2005 to 2013 and from 1998 to 2000 and was a director of Warner Chilcott in 2013 and from 1996 to 2000. From 2001 to 2004 Mr. Herendeen was Executive Vice President and Chief Financial Officer of MedPointe Inc. a specialty pharmaceutical company acquired by Meda AB. since 2014.
Age 59
Tenure 10 years
Professional MarksMBA
Address 10 Sylvan Way, Parsippany, NJ, United States, 07054
Phone973 822 7000
Webhttps://www.zoetis.com
Herendeen graduated from Boston College with a bachelor’s degree in Business Administration, and earned a MBA degree from the University of Virginia’s Darden School of Business.

Zoetis Management Efficiency

The company has Return on Asset of 0.1315 % which means that on every $100 spent on assets, it made $0.1315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4982 %, implying that it generated $0.4982 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Capital Employed is likely to drop 0.15 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024.
The company has 6.8 B in debt with debt to equity (D/E) ratio of 1.48, which is OK given its current industry classification. Zoetis Inc has a current ratio of 2.14, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Zoetis until it has trouble settling it off, either with new capital or with free cash flow. So, Zoetis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zoetis Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zoetis to invest in growth at high rates of return. When we think about Zoetis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

CFO Age

Timothy CoughlinNeurocrine Biosciences
48
Matt AbernethyNeurocrine Biosciences
37
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis Inc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 12100 people. Zoetis Inc (ZTS) is traded on New York Stock Exchange in USA. It is located in 10 Sylvan Way, Parsippany, NJ, United States, 07054 and employs 14,100 people. Zoetis is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Zoetis Inc Leadership Team

Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Steven Frank, Vice Relations
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Timothy Bettington, Executive Vice President and President U.S. Operations
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
William Price, VP Officer
Catherine Knupp, Executive Vice President, President - Research and Development
Jeannette Astorga, Executive Officer
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Antoinette Leatherberry, Independent Director
Nick Ashton, Executive Supply
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development
Sandra Beaty, Executive Vice President - Corporate Affairs
Robert Kelly, Executive Vice President and President International Operations
J McFarland, Executive Vice President and Chief Medical Officer
Robert Polzer, Executive Vice President and Presidentident of Research and Development
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses
Juan Alaix, Chief Executive Officer, Director

Zoetis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zoetis Inc is a strong investment it is important to analyze Zoetis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zoetis' future performance. For an informed investment choice regarding Zoetis Stock, refer to the following important reports:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zoetis Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Zoetis Stock analysis

When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Is Zoetis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zoetis. If investors know Zoetis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zoetis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.164
Dividend Share
1.5
Earnings Share
5.07
Revenue Per Share
18.527
Quarterly Revenue Growth
0.085
The market value of Zoetis Inc is measured differently than its book value, which is the value of Zoetis that is recorded on the company's balance sheet. Investors also form their own opinion of Zoetis' value that differs from its market value or its book value, called intrinsic value, which is Zoetis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zoetis' market value can be influenced by many factors that don't directly affect Zoetis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zoetis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zoetis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.